Real World Evidence Undercuts Value Of Hereditary Angioedema Drugs In ICER Analysis Update

But results of the re-analysis of three HAE treatments aren’t necessarily expected to be typical for RWE-based updates undertaken in the future by the Institute for Clinical and Economic Review.

Does RWE offer a more accurate view of drug benefit and risk? • Source: Alamy

The results of an Institute for Clinical and Economic Review pilot study using real world evidence to update and supplement its cost effectiveness reports on drugs for hereditary angioedema with accelerated approvals raise significant questions about the prices of Takeda Pharmaceutical Co. Ltd.’s Takhzyro and Cinryze and CSL Behring Mexico’s Haegarda.

The three treatments are indicated for prophylaxis of HAE, a rare condition. In 2018, ICER concluded that long-term prophylaxis with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Real-World Evidence

More from Clinical Trials